ArticleHematology. American Society of Hematology. Education Program2022

Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax.

Lydia ScarfòPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.